A synergistic small-molecule combination directly eradicates diverse prion strain structures.

A synergistic small-molecule combination directly eradicates diverse prion strain structures.
复制标题

DOI:
10.1038/nchembio.246
复制
发表时间:
2009-12
影响因子:
14.8
通讯作者:
Shorter J
Shorter J
中科院分区:
生物学1区
文献类型:
--
作者:
Roberts BE;Duennwald ML;Wang H;Chung C;Lopreiato NP;Sweeny EA;Knight MN;Shorter J

文献摘要

参考文献

被引文献

相似文献

安全根除朊病毒、淀粉样蛋白和前淀粉样蛋白寡聚体可以改善几种致命的神经退行性疾病。然而,小分子药物是否可以直接拮抗整个谱系的不同淀粉样蛋白结构或构成不同疾病状态的“菌株”尚不清楚。在这里,我们使用酵母朊病毒蛋白 Sup35 研究了这个问题。我们已经确定了表没食子儿茶素-3-没食子酸酯 (EGCG) 如何阻断合成的 Sup35 朊病毒发生、消除预先形成的 Sup35 朊病毒以及破坏分子间和分子内朊病毒接触。出乎意料的是,这些直接活动是菌株选择性的,改变了可接触的感染形式的库,并促进了一种新的朊病毒菌株的出现,该菌株配置了原始的、耐 EGCG 的分子间接触。在体内,EGCG 可以治愈并阻止诱导敏感菌株,但不能诱导耐药菌株,并引发从敏感菌株向耐药菌株的转变。重要的是,4,5-双-(4-甲氧基苯胺基)邻苯二甲酰亚胺直接拮抗耐 EGCG 的朊病毒,并与 EGCG 协同消除多种 Sup35 朊病毒株。因此,直接消除完整菌株库的协同小分子组合可能具有相当大的治疗潜力。
Safely eradicating prions, amyloids and preamyloid oligomers may ameliorate several fatal neurodegenerative disorders. Yet, whether small-molecule drugs can directly antagonize the entire spectrum of distinct amyloid structures or ‘strains’ that underlie distinct disease states is unclear. Here, we investigated this issue using the yeast prion protein Sup35. We have established how epigallocatechin-3-gallate (EGCG) blocks synthetic Sup35 prionogenesis, eliminates preformed Sup35 prions, and disrupts inter- and intra-molecular prion contacts. Unexpectedly, these direct activities were strain selective, altered the repertoire of accessible infectious forms and facilitated emergence of a new prion strain that configured original, EGCG-resistant intermolecular contacts. In vivo, EGCG cured and prevented induction of susceptible but not resistant strains, and elicited switching from susceptible to resistant forms. Importantly, 4,5-bis-(4-methoxyanilino)phthalimide directly antagonized EGCG-resistant prions and synergized with EGCG to eliminate diverse Sup35 prion strains. Thus, synergistic small-molecule combinations that directly eradicate complete strain repertoires likely hold considerable therapeutic potential.
DOI: 10.1073/pnas.022662599
发表时间: 2002-02-05
影响因子: 11.1
作者:
O'Nuallain, B;Wetzel, R
通讯作者: Wetzel, R
DOI: 10.1073/pnas.0611503104
发表时间: 2007-02-20
影响因子: 11.1
作者:
Mukhopadhyay, Samrat;Krishnan, Rajaraman;Deniz, Ashok A.
通讯作者: Deniz, Ashok A.
DOI: 10.1016/j.neulet.2005.06.053
发表时间: 2005-11-11
影响因子: 2.5
作者:
Kocisko, DA;Engel, AL;Caughey, B
通讯作者: Caughey, B
DOI: 10.1126/science.273.5275.622
发表时间: 1996-08-02
期刊: SCIENCE
影响因子: 56.9
作者:
Patino, MM;Liu, JJ;Lindquist, S
通讯作者: Lindquist, S
DOI: 10.1038/nature03679
发表时间: 2005-06-09
期刊: NATURE
影响因子: 64.8
作者:
Krishnan, R;Lindquist, SL
通讯作者: Lindquist, SL